Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

SIMPLE SUMMARY: The IMbrave150 trial led to the approval of atezolizumab and bevacizumab for the treatment of unresectable hepatocellular carcinoma (HCC). We performed a retrospective multicenter study including 115 patients with unresectable HCC treated with atezolizumab and bevacizumab, revealing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sho, Takuya, Suda, Goki, Yamamoto, Yoshiya, Furuya, Ken, Baba, Masaru, Ogawa, Koji, Kubo, Akinori, Tokuchi, Yoshimasa, Fu, Qingjie, Yang, Zijian, Kimura, Megumi, Kitagataya, Takashi, Maehara, Osamu, Ohnishi, Shunsuke, Nakamura, Akihisa, Yamada, Ren, Ohara, Masatsugu, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Suzuki, Kazuharu, Izumi, Takaaki, Meguro, Takashi, Terashita, Katsumi, Takagi, Tomofumi, Ito, Jun, Kobayashi, Tomoe, Miyagishima, Takuto, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405784/
https://www.ncbi.nlm.nih.gov/pubmed/36010930
http://dx.doi.org/10.3390/cancers14163938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405784/
https://www.ncbi.nlm.nih.gov/pubmed/36010930
http://dx.doi.org/10.3390/cancers14163938

Ejemplares similares